Stevanato Group Posts Record High‑Value Revenue and Strong 2025 Results, Sets Upbeat 2026 Outlook
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Stevanato Group ( (STVN) ).
On March 4, 2026, Stevanato Group reported that fourth‑quarter 2025 revenue rose 5% year‑on‑year to €346.5 million, with high‑value solutions reaching a record 49% of sales and lifting gross and adjusted EBITDA margins. For full‑year 2025, revenue grew 7% to €1.186 billion, high‑value solutions accounted for 46% of revenue, and diluted EPS advanced 19% to €0.51 as strong Biopharmaceutical and Diagnostic Solutions performance offset a planned decline in the lower‑margin Engineering segment.
The company generated €18.4 million of positive free cash flow in 2025 while maintaining significant capex to ramp new plants in Indiana and Italy, ending the year with €130.6 million in cash and €337.7 million in net debt. Management highlighted biologics and GLP‑1 products as key growth drivers and issued fiscal 2026 guidance calling for revenue of €1.26–€1.29 billion and higher adjusted profitability, underscoring confidence in further margin expansion as utilization and efficiency improve at new facilities.
The most recent analyst rating on (STVN) stock is a Buy with a $14.73 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.
Spark’s Take on STVN Stock
According to Spark, TipRanks’ AI Analyst, STVN is a Neutral.
The score is supported by a strong balance sheet and constructive earnings-call momentum (growth in high-value solutions and margin expansion with maintained guidance). It is held back by weak cash flow conversion and a bearish technical setup, with valuation also on the expensive side given the high P/E and low dividend yield.
To see Spark’s full report on STVN stock, click here.
More about Stevanato Group
Stevanato Group S.p.A., listed on the NYSE under the ticker STVN, is a global provider of drug containment, drug delivery and diagnostic solutions serving pharmaceutical, biotechnology and life sciences customers. The company focuses on high‑value, proprietary containment and delivery products and is expanding manufacturing capacity, particularly in biologics and GLP‑1 therapies, supported by facilities in Italy and the U.S.
Average Trading Volume: 589,415
Technical Sentiment Signal: Sell
Current Market Cap: $4.02B
See more data about STVN stock on TipRanks’ Stock Analysis page.
